Psych CASC / OSCE · Addiction psychiatry
Explaining alcohol withdrawal, thiamine, and recovery medications — CASC communication station
MRCPsych/FRANZCP-style communication station: explain AUD and withdrawal timeline, Wernicke prevention, CIWA-guided detox, naltrexone/acamprosate/disulfiram options with plain-language doses and safety, psychosocial aftercare, non-stigmatising language.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar on the ward. [1]
Candidate instructions. Explain alcohol withdrawal and why seizures/delirium can occur after stopping; explain thiamine (Wernicke prevention) in plain language; outline short-term benzodiazepine detox versus longer-term recovery medicines (naltrexone, acamprosate, supervised disulfiram); reduce stigma; address partner anger; agree a follow-up and safety-net plan. Check understanding. [2][3][4]
Candidate scenario
Patient: “If alcohol is the problem, why did you give me more drugs?” Partner: “He nearly died stopping — that means he can never stop.” Observations are now stable; CIWA-Ar is low; he is eating. [1][2]
Marking domains
- Empathy and de-escalation without defensiveness
- Accurate plain-language explanation of dependence, withdrawal timing, seizures/DT risk
- Explains benzodiazepines as short-term medical detox, not indefinite “replacement addiction” when protocolised
- Explains thiamine for brain energy pathways / Wernicke risk without jargon overload
- Offers recovery medicines with key safety points (naltrexone and opioids; acamprosate schedule; disulfiram alcohol reaction)
- Psychosocial aftercare and mutual aid options
- Shared decisions, teach-back, follow-up timing, crisis plan
Reveal assessor key
Open. Introduce role; acknowledge fear and anger; validate that withdrawal can be dangerous and that their concern is legitimate. [1]
Explain withdrawal. After long heavy use the brain adapts; stopping suddenly can cause shaking, sweating, high pulse, fits (often within about one to two days), and sometimes severe confusion with hallucinations (delirium tremens, often around day two to three). That is why he was monitored and given short-term calming medicine from the benzodiazepine family, adjusted to symptoms.[2]
Thiamine. Heavy drinking and poor nutrition can deplete vitamin B1. Low B1 risks Wernicke’s brain injury (eye movement problems, unsteadiness, confusion). Injections deliver high doses quickly to protect the brain; tablets alone are not enough when risk is high.[3][5]
Not forever hopeless. Alcohol use disorder is a medical condition that often relapses and remits; many people achieve long recovery with support. Stopping carefully with help is safer than unsupervised “cold turkey” after severe dependence.[1]
Medicines for recovery (examples). After detox: naltrexone (often one 50 mg tablet daily) can reduce the reward of drinking — not while on strong opioid painkillers; acamprosate (typically 666 mg three times daily) can help maintain abstinence after detox; disulfiram causes a nasty reaction if alcohol is drunk and must be supervised with clear education. All work best with counselling/psychosocial support, not alone.[4]
Benzodiazepine fear. Used short-term for medical withdrawal under protocol, then stopped — different goal from swapping one long-term dependence for another. [2]
Close. Teach-back; written information; outpatient addiction/GP review; crisis contacts; partner involved with consent. [1][4]
References
- [1]Connor JP, Haber PS, Hall WD Alcohol use disorders. Lancet, 2016.PMID 26343838
- [2]Mayo-Smith MF Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA, 1997.PMID 9214531
- [3]Caine D, Halliday GM, Kril JJ, et al. Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry, 1997.PMID 9010400
- [4]Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry, 2018.PMID 29301420
- [5]Galvin R, Bråthen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol, 2010.PMID 20642790